EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

The Role of Circulating Tumor Cell as a Promising Biomarker in the Evaluation of Pulmonary Nodules: A Prospective Study

Shijie Wang, Changdan Xu, Xiaohong Xu, Weipeng Shao, Guohui Wang, Xiongtao Yang, Liwei Gao, Feng Teng, Hongliang Sun, Yue Zhao, Hongxiang Feng, Guangying Zhu

Cancer Research and Treatment · 15.01.2026 · 58 (1) · 128-140

DOI: 10.4143/crt.2024.841 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.01.2026. Verfasst von Shijie Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Pek…. Hauptthemen laut MEDLINE: Neoplastic Cells, Circulating, Biomarkers, Tumor, Lung Neoplasms, Multiple Pulmonary Nodules. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: China-Japan Friendship Hospital Talent Introduction Research Startup Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Our previous study showed that circulating tumor cell (CTC) count combined with gene mutation detection might help differentiate benign and malignant pulmonary nodules (PNs). Herein, we aimed to expand the study cohort and conduct further sequencing analysis.Materials and Methods Patients with PNs were included, and CTCs were identified before operation. Low-coverage whole-genome sequencing (LC-WGS) and lung cancer-related targeted gene sequencing were performed on CTCs. The diagnostic efficacy was evaluated by receiver operating characteristic (ROC) curve. The differences in CTC counts among subgroups classified by demographic–clinical characteristics were analyzed. LC-WGS–based copy number variation (CNV) analysis and targeted gene mutation analysis were conducted.

Results

A total of 172 patients were included. CTC count of 2.5 was identified by the ROC curves as the optimal diagnostic cutoff. The sensitivity and specificity of CTC count for differentiating benign and malignant PNs were 54.2% and 78.6%, respectively. The diagnostic sensitivity and specificity of combined CTC count, radiological nodule type, and any malignant imaging features were 84.7% and 71.4%, respectively. The CTC counts were significantly greater in patients with aggressive tumors, later stage, and spread through air spaces. CTCs from malignant cases had more CNVs than those from benign cases.

Conclusion

CTC count can be used in identifying malignant PNs. The diagnostic efficacy can be improved if combined with computed tomography imaging characteristics. Further CNV analysis might help differential diagnosis. Greater CTC count might suggest more aggressive tumors. CTC detection can provide important information and guidance for subsequent management of PNs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Cells, CirculatingBiomarkers, TumorLung NeoplasmsMultiple Pulmonary NodulesSolitary Pulmonary NoduleHumansFemaleMaleMiddle AgedProspective StudiesAgedAdultROC CurveDNA Copy Number VariationsWhole Genome SequencingMutation

Stichwörter der Autor:innen

Circulating tumor cellCopy number variationEarly diagnosis of lung cancerGene sequencingPulmonary nodule

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Radiation Oncology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Medical Record, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Department of Thoracic Surgical Ward Ⅱ, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
  • Department of Radiation Oncology, Tianjin First Central Hospital, Tianjin, China.
  • Department of Oncology, Beijing Changping Hospital, Beijing, China.

Förderung

  • China-Japan Friendship Hospital Talent Introduction Research Startup Foundation

Zitieren

APA

Wang, S., Xu, C., Xu, X., Shao, W., Wang, G., Yang, X., Gao, L., Teng, F., Sun, H., Zhao, Y., Feng, H., & Zhu, G. (2026). The Role of Circulating Tumor Cell as a Promising Biomarker in the Evaluation of Pulmonary Nodules: A Prospective Study. Cancer Research and Treatment, 58(1), 128-140. https://doi.org/10.4143/crt.2024.841

Vancouver

Wang S, Xu C, Xu X, Shao W, Wang G, Yang X, et al. The Role of Circulating Tumor Cell as a Promising Biomarker in the Evaluation of Pulmonary Nodules: A Prospective Study. Cancer Research and Treatment. 2026;58(1):128-140. doi:10.4143/crt.2024.841

BibTeX
@article{Wang2026,
  author = {Wang, Shijie and Xu, Changdan and Xu, Xiaohong and Shao, Weipeng and Wang, Guohui and Yang, Xiongtao and Gao, Liwei and Teng, Feng and Sun, Hongliang and Zhao, Yue and Feng, Hongxiang and Zhu, Guangying},
  title = {The Role of Circulating Tumor Cell as a Promising Biomarker in the Evaluation of Pulmonary Nodules: A Prospective Study},
  journal = {Cancer Research and Treatment},
  year = {2026},
  volume = {58},
  number = {1},
  pages = {128--140},
  doi = {10.4143/crt.2024.841}
}
Kostenlos starten →